{"id":"nadroparin-calcium","rwe":[{"pmid":"41087918","year":"2025","title":"Brucellosis complicated by disseminated intravascular coagulation and liver injury: a case report and review of the literature.","finding":"","journal":"BMC infectious diseases","studyType":"Clinical Study"},{"pmid":"40890664","year":"2025","title":"Efficacy and safety study of tranexamic acid combined with low-molecular-weight heparin and nadroparin calcium in postoperative application after joint replacement: a retrospective cohort study.","finding":"","journal":"BMC musculoskeletal disorders","studyType":"Clinical Study"},{"pmid":"40196365","year":"2025","title":"Low-molecular-weight heparins utilization in pregnant and postpartum women: a real-world analysis in China (2016-2021).","finding":"","journal":"Frontiers in pharmacology","studyType":"Clinical Study"},{"pmid":"40050974","year":"2025","title":"The novel SERPINC1 missense mutation c.1148 T > A (p.L383H) causes hereditary antithrombin deficiency and thromboembolism in a Chinese family: a case report.","finding":"","journal":"Journal of medical case reports","studyType":"Clinical Study"},{"pmid":"39395952","year":"2024","title":"Cerebral venous sinus thrombosis associated with JAK2 V617F mutation-related pre-primary myelofibrosis: a case report and literature review.","finding":"","journal":"BMC neurology","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"B01AB06","category":"atc"},{"label":"Active","category":"status"},{"label":"Deep venous thrombosis","category":"indication"},{"label":"Anticoagulants","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Fibrinolytic Agents","category":"pharmacology"},{"label":"Hematologic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":108.447,"date":"","count":69,"signal":"Premature baby","source":"DrugCentral FAERS","actionTaken":"Reported 69 times (LLR=108)"},{"llr":108.198,"date":"","count":23,"signal":"Lymphatic fistula","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=108)"},{"llr":107.542,"date":"","count":23,"signal":"Femoral hernia incarcerated","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=108)"},{"llr":99.419,"date":"","count":23,"signal":"Pancreatic steatosis","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=99)"},{"llr":94.596,"date":"","count":34,"signal":"Wound dehiscence","source":"DrugCentral FAERS","actionTaken":"Reported 34 times (LLR=95)"},{"llr":91.468,"date":"","count":23,"signal":"Wound infection pseudomonas","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=91)"},{"llr":84.813,"date":"","count":24,"signal":"Arterial haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 24 times (LLR=85)"},{"llr":83.144,"date":"","count":24,"signal":"Seroma","source":"DrugCentral FAERS","actionTaken":"Reported 24 times (LLR=83)"},{"llr":76.594,"date":"","count":29,"signal":"Tachyarrhythmia","source":"DrugCentral FAERS","actionTaken":"Reported 29 times (LLR=77)"},{"llr":73.173,"date":"","count":91,"signal":"Hyponatraemia","source":"DrugCentral FAERS","actionTaken":"Reported 91 times (LLR=73)"},{"llr":66.533,"date":"","count":30,"signal":"Faecaloma","source":"DrugCentral FAERS","actionTaken":"Reported 30 times (LLR=67)"},{"llr":65.774,"date":"","count":24,"signal":"Aortic valve stenosis","source":"DrugCentral FAERS","actionTaken":"Reported 24 times (LLR=66)"},{"llr":62.049,"date":"","count":65,"signal":"Foetal exposure during pregnancy","source":"DrugCentral FAERS","actionTaken":"Reported 65 times (LLR=62)"},{"llr":60.765,"date":"","count":23,"signal":"Haemarthrosis","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=61)"},{"llr":60.441,"date":"","count":24,"signal":"Hepatic cyst","source":"DrugCentral FAERS","actionTaken":"Reported 24 times (LLR=60)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=NADROPARIN CALCIUM","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:56:19.306463+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Nadroparin Calcium","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:56:33.279578+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:56:31.189371+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NADROPARIN CALCIUM","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:56:32.269951+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Antithrombin-III activator","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:56:33.279158+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2109204/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:56:33.171848+00:00"}},"allNames":"fraxiparin","offLabel":[],"synonyms":["nadroparin","nadroparin calcium","fraxiparine","fraxiparin"],"timeline":[],"aiSummary":"Fraxiparin is a low molecular weight heparin (LMWH) used for thrombosis prophylaxis and treatment of conditions such as Deep Venous Thrombosis and Pulmonary Embolism. It works as an Antithrombin-III activator, a mechanism that involves activating the protein Antithrombin-III to inhibit blood clotting.","approvals":[{"date":"","orphan":false,"company":"","regulator":"Health Canada"}],"brandName":"Fraxiparin","ecosystem":[{"indication":"Deep venous thrombosis","otherDrugs":[{"name":"bemiparin","slug":"bemiparin","company":"Pfizer Inc"},{"name":"enoxaparin sodium","slug":"enoxaparin-sodium","company":"Sanofi Aventis Us"},{"name":"fondaparinux","slug":"fondaparinux","company":"Mylan Ireland Ltd"},{"name":"heparin","slug":"heparin","company":"Organon Usa Inc"}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Fraxiparin exerts its anticoagulant effect by binding to antithrombin III, which inactivates Factor Xa and thrombin, thereby inhibiting the coagulation cascade."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Nadroparin_calcium","title":"Nadroparin calcium","extract":"Nadroparin is an anticoagulant belonging to a class of drugs called low molecular weight heparins (LMWHs). Nadroparin was developed by Sanofi-Synthélabo."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5162","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NADROPARIN%20CALCIUM","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NADROPARIN CALCIUM","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Nadroparin_calcium","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T14:35:41.458125","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:56:35.024559+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"heparin","drugSlug":"heparin","fdaApproval":"1939-02-09","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"enoxaparin sodium","drugSlug":"enoxaparin-sodium","fdaApproval":"1993-03-29","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"bemiparin","drugSlug":"bemiparin","fdaApproval":"1994-12-22","relationship":"same-class"}],"genericName":"nadroparin calcium","indications":{"approved":[{"name":"Deep venous thrombosis","source":"DrugCentral","snomedId":128053003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"heparin","brandName":"heparin","genericName":"heparin","approvalYear":"1939","relationship":"same-class"},{"drugId":"enoxaparin-sodium","brandName":"enoxaparin sodium","genericName":"enoxaparin sodium","approvalYear":"1993","relationship":"same-class"},{"drugId":"bemiparin","brandName":"bemiparin","genericName":"bemiparin","approvalYear":"1994","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07140211","phase":"PHASE3","title":"Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis","status":"RECRUITING","sponsor":"Marc Blondon","startDate":"2025-10-15","conditions":["Venous Thromboembolism (VTE)","Postpartum"],"enrollment":9200,"completionDate":"2030-08"},{"nctId":"NCT04536272","phase":"PHASE3","title":"Reduced Anticoagulation Targets in ECLS (RATE)","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2020-10-01","conditions":["Heart Failure","Respiratory Failure","Extracorporeal Membrane Oxygenation","Bleeding","Thrombosis"],"enrollment":330,"completionDate":"2025-03-07"},{"nctId":"NCT04645550","phase":"PHASE4","title":"Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）","status":"COMPLETED","sponsor":"Northern Jiangsu People's Hospital","startDate":"2020-11-22","conditions":["Cirrhosis","Splenectomy; Status","Venous Thrombosis","Hypertension, Portal"],"enrollment":120,"completionDate":"2023-12-31"},{"nctId":"NCT02987946","phase":"NA","title":"Leiden Trial in Prevention of Post-Operative ThromboEmbolic Events","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2016-12","conditions":["Deep-Venous Thrombosis"],"enrollment":280,"completionDate":"2024-09"},{"nctId":"NCT06494878","phase":"PHASE3","title":"The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2025-04","conditions":["Venous Thromboembolism","Postpartum Period","Aspirin","Low Molecular Weight Heparin"],"enrollment":8805,"completionDate":"2030-12"},{"nctId":"NCT04507178","phase":"PHASE2","title":"Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2022-02-02","conditions":["Aneurysmal Subarachnoid Hemorrhage","Delayed Cerebral Ischemia"],"enrollment":100,"completionDate":"2027-04-01"},{"nctId":"NCT05957146","phase":"","title":"Kinetics of Extracellular Vesicles in Hemodialysis","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2023-11-07","conditions":["End-stage Kidney Disease"],"enrollment":6,"completionDate":"2024-02-09"},{"nctId":"NCT04508855","phase":"","title":"Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)","status":"WITHDRAWN","sponsor":"AHEPA University Hospital","startDate":"2020-08-01","conditions":["Cancer","Atrial Fibrillation"],"enrollment":0,"completionDate":"2023-12"},{"nctId":"NCT04066764","phase":"PHASE3","title":"Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-08","conditions":["Venous Thromboembolism"],"enrollment":200,"completionDate":"2024-10-01"},{"nctId":"NCT04067505","phase":"PHASE3","title":"Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-18","conditions":["May-Thurner Syndrome"],"enrollment":224,"completionDate":"2024-12-31"},{"nctId":"NCT06319131","phase":"NA","title":"Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-05-01","conditions":["Portal Vein Thrombosis"],"enrollment":84,"completionDate":"2026-05-30"},{"nctId":"NCT04373707","phase":"PHASE4","title":"Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2020-05-13","conditions":["COVID","Thrombosis","Pulmonary Embolism","Deep Vein Thrombosis"],"enrollment":1000,"completionDate":"2021-09-14"},{"nctId":"NCT05926518","phase":"","title":"Anti-Xa Level With Thromboprophylactic Dosage Nadroparin in Critically Ill COVID-19 and Non-COVID-19 Patients","status":"COMPLETED","sponsor":"Rijnstate Hospital","startDate":"2020-11-01","conditions":["Critical Illness","Therapeutic Drug Monitoring","Venous Thromboembolism"],"enrollment":62,"completionDate":"2022-11-23"},{"nctId":"NCT05621915","phase":"","title":"Nadroparin Pharmacokinetics in Different Stages of COVID-19","status":"COMPLETED","sponsor":"Medical University of Lublin","startDate":"2021-02-01","conditions":["Thrombosis","Nadroparin","COVID-19","Mechanical Ventilation","Anticoagulants and Bleeding Disorders"],"enrollment":43,"completionDate":"2022-04-15"},{"nctId":"NCT03005444","phase":"NA","title":"Anticoagulation for Advanced Cirrhotic Patients After TIPS","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2017-06-14","conditions":["Liver Cirrhosis"],"enrollment":254,"completionDate":"2024-12-31"},{"nctId":"NCT04976543","phase":"PHASE4","title":"Safety of Anticoagulant Therapy After Endoscopic Treatment","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2020-02-01","conditions":["Cirrhosis","Portal Vein Thrombosis","Esophageal and Gastric Varices","Anticoagulant-induced Bleeding"],"enrollment":86,"completionDate":"2022-06-28"},{"nctId":"NCT05545475","phase":"","title":"Safety of Anticoagulant Therapy After Tissue Glue for Gastric Varices","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2022-01-01","conditions":["Anticoagulants and Bleeding Disorders","Tissue Adhesion","Gastric Varices Bleeding"],"enrollment":100,"completionDate":"2024-01-18"},{"nctId":"NCT01828697","phase":"PHASE4","title":"Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2013-04-24","conditions":["Deep Venous Thrombosis","Pulmonary Embolism"],"enrollment":1110,"completionDate":"2021-10-31"},{"nctId":"NCT04982055","phase":"PHASE4","title":"Intravenous Versus Subcutaneous Administration of Low Molecular Weight Heparin for Thromboprophylaxis in Critically Ill Patients","status":"COMPLETED","sponsor":"Clinique Saint Pierre Ottignies","startDate":"2015-04-08","conditions":["Critical Illness"],"enrollment":60,"completionDate":"2020-12-31"},{"nctId":"NCT04173429","phase":"PHASE4","title":"Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2017-01-01","conditions":["Liver Cirrhosis","Portal Vein Thrombosis"],"enrollment":64,"completionDate":"2020-01-31"},{"nctId":"NCT03671174","phase":"NA","title":"Immunosuppressant Regimens for Living Fetuses Study","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2019-08-02","conditions":["Undifferentiated Connective Tissue Disease","Recurrent Pregnancy Loss"],"enrollment":420,"completionDate":"2023-02"},{"nctId":"NCT01727427","phase":"","title":"Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients","status":"COMPLETED","sponsor":"G. d'Annunzio University","startDate":"2012-11","conditions":["Unsuspected Pulmonary Embolism"],"enrollment":695,"completionDate":"2017-12"},{"nctId":"NCT02247414","phase":"PHASE4","title":"Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection","status":"COMPLETED","sponsor":"Yangzhou University","startDate":"2014-09","conditions":["Cirrhosis","Hypertension","Status;Splenectomy","Venous Thrombosis"],"enrollment":124,"completionDate":"2018-04"},{"nctId":"NCT02238444","phase":"PHASE4","title":"Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy","status":"UNKNOWN","sponsor":"Yangzhou University","startDate":"2014-09-01","conditions":["Cirrhosis","Hypertension","Venous Thrombosis","Status; Splenectomy"],"enrollment":60,"completionDate":"2019-09-30"},{"nctId":"NCT01431456","phase":"PHASE3","title":"Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery","status":"COMPLETED","sponsor":"Martini Hospital Groningen","startDate":"2013-09","conditions":["Venous Thromboembolism"],"enrollment":148,"completionDate":"2014-10"},{"nctId":"NCT00421538","phase":"PHASE3","title":"Randomized Controlled Trial of Anticoagulation vs. Placebo for a First Symptomatic Isolated Distal Deep-vein Thrombosis (IDDVT)","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2008-01","conditions":["Distal (Calf) Deep-vein Thrombosis"],"enrollment":260,"completionDate":"2015-08"},{"nctId":"NCT00312013","phase":"PHASE3","title":"Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05","conditions":["Thrombosis, Venous"],"enrollment":503,"completionDate":"2009-07"},{"nctId":"NCT02526303","phase":"NA","title":"Anticoagulation for Non-occlusive Portal Vein Thrombosis in Patients With Liver Cirrhosis","status":"WITHDRAWN","sponsor":"Air Force Military Medical University, China","startDate":"","conditions":["Liver Cirrhosis","Portal Vein Thrombosis","Anticoagulation"],"enrollment":0,"completionDate":""},{"nctId":"NCT02957877","phase":"PHASE4","title":"LMWH Infusion as Anticoagulation for Home HD","status":"UNKNOWN","sponsor":"Alice Ho Miu Ling Nethersole Hospital","startDate":"2016-03","conditions":["Endstage Renal Disease"],"enrollment":12,"completionDate":"2018-05"},{"nctId":"NCT01542762","phase":"NA","title":"Pot-Cast: Thrombosis Prophylaxis During Plaster Cast Lower Leg Immobilisation","status":"COMPLETED","sponsor":"Suzanne C. Cannegieter, MD PhD","startDate":"2012-03","conditions":["Deep Venous Thrombosis","Pulmonary Embolism"],"enrollment":1500,"completionDate":"2016-09"},{"nctId":"NCT01542723","phase":"NA","title":"Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy","status":"COMPLETED","sponsor":"Suzanne C. Cannegieter, MD PhD","startDate":"2012-05","conditions":["Deep Venous Thrombosis","Pulmonary Embolism"],"enrollment":1500,"completionDate":"2016-09"},{"nctId":"NCT00827554","phase":"PHASE2,PHASE3","title":"The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2008-12","conditions":["Hepatocellular Carcinoma"],"enrollment":100,"completionDate":"2011-10"},{"nctId":"NCT00843492","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12","conditions":["Thrombosis, Venous"],"enrollment":1351,"completionDate":"2010-06"},{"nctId":"NCT02630095","phase":"PHASE4","title":"The Effect of Anticoagulation in Cirrhotic Patients With Portal Vein Thrombosis：A Multicenter RCT","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2015-12","conditions":["Portal Vein Thrombosis","Liver Cirrhosis"],"enrollment":96,"completionDate":"2018-09"},{"nctId":"NCT02398357","phase":"PHASE4","title":"The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2015-03","conditions":["Portal Vein Thrombosis","Liver Cirrhosis"],"enrollment":96,"completionDate":"2017-12"},{"nctId":"NCT01064362","phase":"","title":"Hemorrhage Risk Prescribed Arixtra","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-01","conditions":["Thrombosis, Venous"],"enrollment":13442,"completionDate":"2010-06"},{"nctId":"NCT01164046","phase":"PHASE3","title":"Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism","status":"TERMINATED","sponsor":"University Medical Center Groningen","startDate":"2010-08","conditions":["Venous Thromboembolism","Neoplasms"],"enrollment":56,"completionDate":"2014-07"},{"nctId":"NCT02295150","phase":"PHASE4","title":"Prophylaxis of Venous Thromboembolism After Bariatric Surgery","status":"UNKNOWN","sponsor":"Rijnstate Hospital","startDate":"2013-03","conditions":["Morbid Obesity","Thromboembolism","Bypass Complications"],"enrollment":50,"completionDate":"2015-06"},{"nctId":"NCT01267305","phase":"NA","title":"The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2011-01","conditions":["Lung Neoplasms","Esophageal Neoplasms","Venous Thromboembolism"],"enrollment":362,"completionDate":"2013-08"},{"nctId":"NCT01980849","phase":"PHASE3","title":"Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer","status":"UNKNOWN","sponsor":"Shengqing Li","startDate":"2013-11","conditions":["Lung Cancer"],"enrollment":272,"completionDate":""},{"nctId":"NCT01862978","phase":"PHASE4","title":"Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke","status":"UNKNOWN","sponsor":"University Hospital, Martin","startDate":"2013-05","conditions":["Acute Ischemic Stroke"],"enrollment":150,"completionDate":"2015-12"},{"nctId":"NCT00881088","phase":"PHASE2,PHASE3","title":"Prophylaxis of Thromboembolic Complications Trial: Thromboprophylaxis Needed in Below Knee Plaster Cast Immobilization for Ankle and Foot Fractures","status":"UNKNOWN","sponsor":"Red Cross Hospital Beverwijk","startDate":"2009-04","conditions":["Deep Vein Thrombosis","Pulmonary Embolism"],"enrollment":669,"completionDate":"2013-04"},{"nctId":"NCT01531829","phase":"PHASE4","title":"Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD","status":"UNKNOWN","sponsor":"Beijing Chao Yang Hospital","startDate":"2009-07","conditions":["Pulmonary Thromboembolisms","Pulmonary Embolism"],"enrollment":460,"completionDate":"2012-12"},{"nctId":"NCT01523652","phase":"","title":"Pharmacokinetic Study on the Administration of Nadroparin Dosing Serum HGF in Gynecological Patients","status":"COMPLETED","sponsor":"Azienda Ospedaliera San Giovanni Battista","startDate":"2007-11","conditions":["Genital Diseases, Female","Ovarian Neoplasms","Urogenital Neoplasms"],"enrollment":29,"completionDate":"2008-11"},{"nctId":"NCT00951574","phase":"PHASE3","title":"Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)","status":"COMPLETED","sponsor":"Italfarmaco","startDate":"2003-10","conditions":["Advanced Cancer","Metastatic Cancer"],"enrollment":1166,"completionDate":"2008-07"},{"nctId":"NCT01097148","phase":"PHASE4","title":"Peri -and Postoperative Drug Therapy Schedules for Morbidly Obese Patients","status":"COMPLETED","sponsor":"St. Antonius Hospital","startDate":"2009-11","conditions":["Obese","Atracurium","Cefazolin","Morphine","Nadroparin"],"enrollment":20,"completionDate":"2010-04"},{"nctId":"NCT01019655","phase":"PHASE3","title":"Heparin for Pregnant Women With Thrombophilia","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2010-01","conditions":["Pregnancy and Thrombophilia"],"enrollment":300,"completionDate":"2012-12"},{"nctId":"NCT00286273","phase":"PHASE4","title":"Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration","status":"COMPLETED","sponsor":"Onze Lieve Vrouwe Gasthuis","startDate":"2003-03","conditions":["Kidney Failure, Acute"],"enrollment":215,"completionDate":"2008-03"},{"nctId":"NCT00965328","phase":"PHASE4","title":"Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration","status":"COMPLETED","sponsor":"Onze Lieve Vrouwe Gasthuis","startDate":"2007-02","conditions":["Kidney","Acute Renal Failure","Multiple Organ Failure"],"enrollment":14,"completionDate":"2008-05"},{"nctId":"NCT00796692","phase":"PHASE4","title":"Nadroparin for the Initial Treatment of Pulmonary Thromboembolism","status":"COMPLETED","sponsor":"Beijing Chao Yang Hospital","startDate":"2002-06","conditions":["Pulmonary Embolism","Thromboembolism","Vascular Diseases","Thrombosis"],"enrollment":274,"completionDate":"2006-02"},{"nctId":"NCT00669721","phase":"NA","title":"OPG and RANKL Plasma Level After Administration of Unfractionated Heparin (UFH) and Low-Molecular-Weight Heparin (LMWH) in Hemodialysis","status":"UNKNOWN","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2008-03","conditions":["Renal Failure","Hemodialysis"],"enrollment":40,"completionDate":"2008-06"},{"nctId":"NCT00303407","phase":"","title":"Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care","status":"TERMINATED","sponsor":"University Hospital, Geneva","startDate":"2001-01","conditions":["Cancer","Venous Thromboembolism"],"enrollment":0,"completionDate":"2002-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005821","UNII":"LIA7Z4002P","INN_ID":"5750","RXNORM":"67031","UMLSCUI":"C0206232","chemblId":"CHEMBL2109204","ChEMBL_ID":"CHEMBL2109204","DRUGBANK_ID":"DB08813","PUBCHEM_CID":"772","SNOMEDCT_US":"698278006","SECONDARY_CAS_RN":"9005-49-6","MESH_DESCRIPTOR_UI":"D017762"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":93,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"B01AB06","allCodes":["B01AB06"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Oct 14","pmid":"41087918","title":"Brucellosis complicated by disseminated intravascular coagulation and liver injury: a case report and review of the literature.","journal":"BMC infectious diseases"},{"date":"2025 Sep 1","pmid":"40890664","title":"Efficacy and safety study of tranexamic acid combined with low-molecular-weight heparin and nadroparin calcium in postoperative application after joint replacement: a retrospective cohort study.","journal":"BMC musculoskeletal disorders"},{"date":"2025","pmid":"40196365","title":"Low-molecular-weight heparins utilization in pregnant and postpartum women: a real-world analysis in China (2016-2021).","journal":"Frontiers in pharmacology"},{"date":"2025 Mar 6","pmid":"40050974","title":"The novel SERPINC1 missense mutation c.1148 T > A (p.L383H) causes hereditary antithrombin deficiency and thromboembolism in a Chinese family: a case report.","journal":"Journal of medical case reports"},{"date":"2024 Oct 12","pmid":"39395952","title":"Cerebral venous sinus thrombosis associated with JAK2 V617F mutation-related pre-primary myelofibrosis: a case report and literature review.","journal":"BMC neurology"}],"_healthCanadaChecked":true,"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Oligosaccharide","firstApprovalDate":"2018","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:56:35.024559+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}